$16.6 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 136 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF TRput | $510,346,000 | – | 1,365,000 | +100.0% | 3.07% | – |
| ARMK | New | ARAMARK | $424,202,000 | – | 11,023,949 | +100.0% | 2.55% | – |
| XLNX | New | XILINX INC | $362,364,000 | – | 2,556,000 | +100.0% | 2.18% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $351,056,000 | – | 2,246,900 | +100.0% | 2.11% | – |
| RTX | New | RAYTHEON TECHNOLOGIES CORP | $324,820,000 | – | 4,542,306 | +100.0% | 1.95% | – |
| AVGO | New | BROADCOM INC | $272,778,000 | – | 622,995 | +100.0% | 1.64% | – |
| WORK | New | SLACK TECHNOLOGIES INC | $207,496,000 | – | 4,912,300 | +100.0% | 1.25% | – |
| IPHI | New | INPHI CORP | $198,951,000 | – | 1,239,800 | +100.0% | 1.20% | – |
| QGEN | New | QIAGEN NV | $172,120,000 | – | 3,256,771 | +100.0% | 1.04% | – |
| LU | New | LUFAX HOLDING LTD | $76,080,000 | – | 5,357,750 | +100.0% | 0.46% | – |
| BCAB | New | BIOATLA INC | $66,900,000 | – | 1,967,060 | +100.0% | 0.40% | – |
| IONS | New | IONIS PHARMACEUTICALS INC | $42,405,000 | – | 750,000 | +100.0% | 0.26% | – |
| New | INSMED INCnote 1.750% 1/1 | $36,552,000 | – | 32,500,000 | +100.0% | 0.22% | – | |
| NVAX | New | NOVAVAX INC | $30,665,000 | – | 275,000 | +100.0% | 0.18% | – |
| PANA | New | PANACEA ACQUISITION CORPcl a | $29,250,000 | – | 2,500,000 | +100.0% | 0.18% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $28,863,000 | – | 1,250,000 | +100.0% | 0.17% | – |
| CLVR | New | CLEVER LEAVES HOLDINGS INC | $28,730,000 | – | 2,478,079 | +100.0% | 0.17% | – |
| BIIB | New | BIOGEN INC | $25,221,000 | – | 103,000 | +100.0% | 0.15% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $21,600,000 | – | 750,000 | +100.0% | 0.13% | – |
| New | IQIYI INCnote 4.000%12/1 | $20,000,000 | – | 20,000,000 | +100.0% | 0.12% | – | |
| PRAX | New | PRAXIS PRECISION MEDICINES I | $13,755,000 | – | 250,000 | +100.0% | 0.08% | – |
| New | NUANCE COMMUNICATIONS INCdbcv 1.000%12/1 | $13,052,000 | – | 7,000,000 | +100.0% | 0.08% | – | |
| XPO | New | XPO LOGISTICS INC | $13,112,000 | – | 110,000 | +100.0% | 0.08% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $12,240,000 | – | 225,000 | +100.0% | 0.07% | – |
| TINVU | New | TIGA ACQUISITION CORPunit 99/99/9999 | $11,426,000 | – | 1,080,000 | +100.0% | 0.07% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $10,968,000 | – | 200,000 | +100.0% | 0.07% | – |
| CASU | New | CASCADE ACQUISITION CORPunit 99/99/9999 | $10,346,000 | – | 990,000 | +100.0% | 0.06% | – |
| KNTE | New | KINNATE BIOPHARMA INC | $9,945,000 | – | 250,000 | +100.0% | 0.06% | – |
| SURF | New | SURFACE ONCOLOGY INC | $9,240,000 | – | 1,000,000 | +100.0% | 0.06% | – |
| New | GOSSAMER BIO INCnote 5.000% 6/0 | $9,032,000 | – | 10,000,000 | +100.0% | 0.05% | – | |
| COGT | New | COGENT BIOSCIENCES INC | $6,738,000 | – | 600,000 | +100.0% | 0.04% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $6,804,000 | – | 400,000 | +100.0% | 0.04% | – |
| IMGN | New | IMMUNOGEN INC | $6,450,000 | – | 1,000,000 | +100.0% | 0.04% | – |
| CRIS | New | CURIS INC | $5,938,000 | – | 725,000 | +100.0% | 0.04% | – |
| MRVL | New | MARVELL TECHNOLOGY GROUP LTDcall | $5,943,000 | – | 125,000 | +100.0% | 0.04% | – |
| STTK | New | SHATTUCK LABS INC | $5,241,000 | – | 100,000 | +100.0% | 0.03% | – |
| TGTX | New | TG THERAPEUTICS INC | $5,202,000 | – | 100,000 | +100.0% | 0.03% | – |
| HMCOU | New | HUMANCO ACQUISITION CORPunit 12/08/2023 | $4,408,000 | – | 400,000 | +100.0% | 0.03% | – |
| MASS | New | 908 DEVICES INC | $4,271,000 | – | 75,000 | +100.0% | 0.03% | – |
| FDMT | New | 4D MOLECULAR THERAPEUTICS IN | $4,145,000 | – | 100,000 | +100.0% | 0.02% | – |
| KURA | New | KURA ONCOLOGY INC | $4,083,000 | – | 125,000 | +100.0% | 0.02% | – |
| New | ISIS PHARMACEUTICALS INC DELnote 1.000%11/1 | $2,733,000 | – | 2,500,000 | +100.0% | 0.02% | – | |
| SBTX | New | SILVERBACK THERAPEUTICS INC | $2,207,000 | – | 47,620 | +100.0% | 0.01% | – |
| CEREW | New | CEREVEL THERAPEUTICS HLDNG I*w exp 06/09/202 | $758,000 | – | 134,175 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| GRIFOLS S A | 33 | Q4 2021 | 0.9% |
| ALPHABET INC | 32 | Q3 2023 | 4.2% |
| SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
| VISA INC | 30 | Q3 2023 | 2.9% |
| WABTEC CORP | 27 | Q3 2023 | 3.6% |
| EXELIXIS INC | 27 | Q3 2023 | 2.8% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
| SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
| Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
| Solid Power, Inc. | February 11, 2022 | ? | ? |
| Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2024-02-12 |
| SC 13G/A | 2024-02-01 |
| SC 13G/A | 2024-01-23 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.